Dr. Langmuir on Vandetanib in Medullary Thyroid Cancer

Video

Peter Langmuir, MD, Executive Director, Medical Science AstraZeneca on Vandetanib in Medullary Thyroid Cancer

Related Videos
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD
Shruti Tiwari, MD
Jeffrey P. Townsend, PhD
Marina Baretti, MD
George R. Simon, MD, FACP, FCCP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Related Content
stock.adobe.com

Toripalimab NDA Under Review in Hong Kong for Nasopharyngeal Carcinoma

April 25th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Jameel Muzaffar, MD

Tivumecirnon Plus Pembrolizumab Shows Activity in Checkpoint Inhibitor–Exposed Recurrent/Metastatic HNSCC

April 21st 2024
Article
Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

September 2nd 2021
Podcast
FDA

FDA Grants Fast Track Designation to LYT-200 in Recurrent/Metastatic HNSCC

April 11th 2024
Article
Oliver Lantz, MD, PhD, a clinical immunologist and researcher at Institut Curie in Paris, France

Investigational Vaccine TG4050 Shows Early Clinical Benefit in HPV– Head and Neck Cancers

April 9th 2024
Article